Skip to main content
Premium Trial:

Request an Annual Quote

The War Goes On

The Science Business Blog at Forbes looks into what it dubs the “gene machine wars.” There, Matthew Herper points out that just weeks after Illumina announced that its HiSeq 2000 could sequence a human genome for about $10,000, that Life Technologies said its SOLiD 4 that could do it for $6,000. Herper says that Illumina won’t lose its place at the top. “Although the news is good for Life and will keep it in the game as the price of decoding the genetic code continues to drop, the specs of this new machine don't seem good enough to upset Illumina's place as the first choice of geneticists,” he writes.

The Scan

Another Resignation

According to the Wall Street Journal, a third advisory panel member has resigned following the US Food and Drug Administration's approval of an Alzheimer's disease drug.

Novavax Finds Its Vaccine Effective

Reuters reports Novavax's SARS-CoV-2 vaccine is more than 90 percent effective in preventing COVID-19.

Can't Be Used

The US Food and Drug Administration says millions of vaccine doses made at an embattled manufacturing facility cannot be used, the New York Times reports.

PLOS Papers on Frozen Shoulder GWAS, Epstein-Barr Effects on Immune Cell Epigenetics, More

In PLOS this week: genome-wide association study of frozen shoulder, epigenetic patterns of Epstein-Barr-infected B lymphocyte cells, and more.